CIK 0000920148
- Large accelerated filer
LABCORP HOLDINGS INC.
Sign in to watch- Ticker
- LH
- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 992588107
- Phone
- +1 336-229-1127
- Business address
- 358 S MAIN ST, BURLINGTON, NC, 27215
- Former names
- LABORATORY CORP OF AMERICA HOLDINGS, NATIONAL HEALTH LABORATORIES HOLDINGS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,241,708
- in 3 filings, $108K under 10b5-1 plans
Net −$1,241,708. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-27 | EISENBERG GLENN A Chief Financial Officer, EVP | Option exercise | +20,033 | 43,628 | ||
| 2024-03-27 | EISENBERG GLENN A Chief Financial Officer, EVP | Shares withheld for taxes | −8,805 | $216.57 | $1.9M | 34,823 |
| 2024-03-27 | EISENBERG GLENN A Chief Financial Officer, EVP | Option exercise · Restricted Stock Unit | −20,033 | 15,706 | ||
| 2024-03-27 | BERBERIAN LANCE EVP, CIO & CTO | Option exercise | +7,697 | 31,313 | ||
| 2024-03-27 | BERBERIAN LANCE EVP, CIO & CTO | Shares withheld for taxes | −3,299 | $216.57 | $714K | 28,014 |
| 2024-03-27 | BERBERIAN LANCE EVP, CIO & CTO | Option exercise · Restricted Stock Unit | −7,697 | 2,100 | ||
| 2024-03-07 | Schroeder Mark S EVP, Pres Diagnostics & COO | Option exercise 10b5-1 | +2,119 | $117.09 | $248K | 10,084.14 |
| 2024-03-07 | Schroeder Mark S EVP, Pres Diagnostics & COO | Sale 10b5-1 | −5,048 | $218.45 | $1.1M | 5,036.14 |
| 2024-03-07 | Schroeder Mark S EVP, Pres Diagnostics & COO | Option exercise · Non-qualified Stock Options 10b5-1 | −2,119 | 0 | ||
| 2024-03-07 | Summy Amy B. EVP, Chief Marketing Officer | Sale 10b5-1 | −227 | $218.45 | $50K | 3,859 |
| 2024-02-21 | EISENBERG GLENN A Chief Financial Officer, EVP | Option exercise | +14,054 | $163.63 | $2.3M | 58,099 |
| 2024-02-21 | EISENBERG GLENN A Chief Financial Officer, EVP | Sale | −18,379 | $215.37 | $4.0M | 39,720 |
| 2024-02-21 | EISENBERG GLENN A Chief Financial Officer, EVP | Sale | −7,907 | $215.68 | $1.7M | 31,813 |
| 2024-02-21 | EISENBERG GLENN A Chief Financial Officer, EVP | Sale | −6,665 | $217.52 | $1.4M | 25,148 |
| 2024-02-21 | EISENBERG GLENN A Chief Financial Officer, EVP | Sale | −1,553 | $217.98 | $339K | 23,595 |
| 2024-02-21 | EISENBERG GLENN A Chief Financial Officer, EVP | Option exercise · Non-qualified Stock Options | −14,054 | 0 | ||
| 2024-02-21 | DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl | Sale | −500 | $215.49 | $108K | 3,400.55 |
| 2024-02-13 | van der Vaart Sandra D EVP, Chief Legal Officer | Sale 10b5-1 | −237 | $226.45 | $54K | 7,636.98 |
| 2024-02-12 | Schechter Adam H President & CEO | Shares withheld for taxes | −1,231 | $227.45 | $280K | 52,994 |
| 2024-02-12 | EISENBERG GLENN A Chief Financial Officer, EVP | Shares withheld for taxes | −215 | $227.45 | $49K | 44,045 |
Page 27 of 28 · 545 trades